EMA Validates Lyme Disease Vaccine Application from Pfizer and Valneva

The European Medicines Agency has validated the Marketing Authorization Application for Pfizer and Valneva's 6-valent Lyme disease vaccine candidate, PF-07307405. This validation marks a significant step towards potentially approving the first vaccine against the tick-borne infection in the European Union, with Pfizer also engaging the U.S. FDA for a similar application.